PC Pharma Limited - Colombo Stock Exchange

More documents

Recommendations

Info

Table 3.1: Health Sector Infrastructure Including Human Resource Item 2007 2008 2009 2010 (a) Government Hospitals (practicing western medicine) (No.) 619 619 555 568 Beds (No.) 62,749 65,835 68,897 69,501 Primary Healthcare Units (No.) 387 411 475 476 Doctors (No.) 11,442 13,026 13,633 14,125 (b) Assistant medical practitioners (No.) 1,244 1,229 1,198 1,158 Nurses (No.) 22,088 22,996 25,549 27,494 Attendants (No.) 7,201 7,184 8,301 8,189 Total government expenditure on health (Rs.Bn) 68.7 74.5 71.5 73.8 Current expenditure (Rs.Bn) 51.7 55.9 58.8 60.5 (a) Provisional Source: CBSL Annual Report (b) Including Intern Medical Officers In Sri Lanka, health care expenditure structure consists of the following expenditure schemes as depicted below Figure 3.2: Healthcare Expenditure Scheme 44% Source: CBSL Annual Report Healthcare Expediture Schemes 0% 2% 5% 49% Government Budget Voluntary health insurance schemes Social health insurance Out-of-pocket payments / Household expenditure Other 8 Introductory Document – PC Pharma Limited
3.4 Pharmaceutical Industry in Sri Lanka Sri Lanka National Pharmaceutical Policy Sri Lanka National Pharmaceutical Policy was established in 1970 following a report submitted by Dr. S. A. Wickramasinghe and Prof. Senaka Bibile with the aim of ensuring that people get good quality pharmaceuticals at the lowest possible prices. Under the integrated National Pharmaceutical Policy a central procuring agency of pharmaceuticals, calling for worldwide bulk tenders were established. The pharmaceuticals purchased were limited to the approved list of the national formulary. The public health sector was compelled to obtain all their requirements from the central buying agency. This policy was watered down by the subsequent governments by permitting the private sector importation of multiple brands. Introduction of the National Pharmaceutical Policy led to the establishment of the State Pharmaceutical Corporation in 1971 this resulted in the dominance of the multinational corporations on the drug trade being successfully broken as they were made to compete with each other and with generic drug producers, enabling the people to obtain pharmaceuticals much cheaper. Branded pharmaceuticals were replaced to a certain extent by generic pharmaceuticals in the prescription and sale of medicines. According to the Chairman of the Sri Lanka Chamber of Pharmaceutical Industry approximately 10% of the country demand for medicine is being met by local manufacturers with the balance being imported. Over the years the number of imported pharmaceuticals has increased significantly. By the year 2000 Sri Lanka had approximately 9000 registered medicinal pharmaceuticals, hundreds of which were non-essential or highly expensive or even dangerous. In 2005 the National Medicinal Drugs Policy (NMDP) was established with the aim of cutting down on drug expenses and getting quality pharmaceuticals at affordable prices. Implementation of the NMDP reduced the number of pharmaceuticals imported, prescribed and sold in Sri Lanka to about 350 varieties. Cosmetic Devices and Drug Authority (CDDA) All Pharmaceutical and medical equipment imports to Sri Lanka are stringently monitored by the drug regulatory arm of the MOH, the Cosmetic Devices and Drug Authority (CDDA). The CDDA ensures that the quality standards of pharmaceuticals and medical devices available to the Sri Lankan market meet the standards set by the authority consistently. Post surveillance procedures ensures that all those responsible for holding and distributing medical products imported to the country are held responsible until such time the products are delivered to the end user for consumption. Introductory Document – PC Pharma Limited 9
Page 3: PC Pharma Limited Introductory Docu
Page 7: Abbreviations CBSL Central Bank of
Page 10 and 11: 5. 5.1 5.2 5.3 5.4 6. 6.1 6.2 7. 7.
Page 12 and 13: Board of Directors Mr. Saheedul Hij
Page 14 and 15: CT Smith Stockbrokers (Pvt) Limited
Page 16 and 17: 3. 3.1 3.2 Overview of the Healthca
Page 20 and 21: Guidelines are in place making it m
Page 22 and 23: 3.5 pharmaceuticals covering a wide
Page 24 and 25: 4. 4.1 Company Profile Group Overvi
Page 26 and 27: 4.3 Pharmaceutical items of superio
Page 28 and 29: 4.5 The company is also involved in
Page 30 and 31: 4.6 Distribution PC Pharma Limited
Page 32 and 33: 4.7 Financial Highlights Salient ex
Page 34 and 35: 4.8 Key Financial Ratios The key fi
Page 36 and 37: 4.11 4.12 IT Infrastructure The per
Page 38 and 39: 5.2 5.3 Underlying Assumptions on W
Page 40 and 41: Risk associated with the Manufactur
Page 42 and 43: Introductory Document - PC Pharma L
Page 44 and 45: Natasha Antoinette Abeyagoonasekera
Page 46 and 47: 7.2 Share Capital Share Allotments
Page 48 and 49: Distribution of Shareholding Distri
Page 50 and 51: 8.1 Mrs. Shanthi Sri Nanda Goonarat
Page 52 and 53: 8.5 8.6 Director’s Emoluments Emo
Page 54 and 55: 10. Corporate Governance Practices
Page 56 and 57: 11. Statutory Declaration Declarati
Page 58 and 59: Audited Financial Statements 48 Int
Page 60 and 61: 50 Introductory Document - PC Pharm
Page 68 and 69:
58 Introductory Document - PC Pharm
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Annexure II - Auditors Report and F
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Interim Financial Statements 96 Int
Page 108 and 109:
show all

PC Pharma Limited - Colombo Stock Exchange

Create successful ePaper yourself

Delete template?

Save as template?